Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Author(s): Franck Morschhauser, MD, PhD1; Loretta Nastoupil, MD2; Pierre Feugier, MD, PhD3; Jean-Marc Schiano de Colella, MD4; Hervé Tilly, MD5; Maria Lia Palomba, MD6; Emmanuel Bachy, MD, PhD7; Christophe Fruchart, MD8; Edward N. Libby, MD9; Rene-Olivier Casasnovas, MD10; Ian W. Flinn, MD, PhD11; Corinne Haioun, MD12; Hervé Maisonneuve, MD13; Loic Ysebaert, MD, PhD14; Nancy L. Bartlett, MD15; Kamal Bouabdallah, MD16; Pauline Brice, MD17; Vincent Ribrag, MD18; Steven Le Gouill, MD, PhD19; Nicolas Daguindau, MD20; Stéphanie Guidez, MD21; Gian Matteo Pica, MD22; Alejandro Martín García-Sancho, MD, PhD23; Armondo López-Guillermo, MD24; Jean-François Larouche, MD25; Kiyoshi Ando, MD26; Maria Gomes da Silva, MD, PhD27; Marc André, MD28; Wu Kalung, MD29; Laurie H. Sehn, MD, MPH30; Koji Izutsu, MD, PhD31; Guillaume Cartron, MD, PhD32; Argyrios Gkasiamis, MD33; Russell Crowe, MA33; Luc Xerri, MD, PhD4; Nathan H. Fowler, MD2; and Gilles Salles, MD6
Source: 10.1200/JCO.22.00843 Journal of Clinical Oncology 40, no. 28 (October 01, 2022) 3239-3245
Original Article
Professional photo of Maem Hussein, MD

Dr. Maen Hussein's Thoughts

Confirming that RR can be an alternative to R chemotherapy as a first line therapy  in advanced stage follicular lymphoma.

ABSTRACT

The RELEVANCE trial (ClinicalTrials.gov identifier: NCT01650701) showed that lenalidomide plus rituximab (R2) provided similar efficacy to rituximab plus chemotherapy (R-chemo) in patients with advanced-stage, previously untreated follicular lymphoma (FL). We report the second interim analysis of the RELEVANCE trial after 6 years of follow-up. Patients with previously untreated grade 1-3a FL were assigned 1:1 to R2 or R-chemo, followed by rituximab maintenance. Coprimary end points were complete response (confirmed/ unconfirmed) at week 120 and progression-free survival (PFS). At median follow-up of 72 months, 6-year PFS was 60% and 59% for R2 and R-chemo, respectively (hazard ratio 5 1.03 [95% CI, 0.84 to 1.27]). Six-year overall survival was estimated to be 89% in both groups. Median PFS and overall survival were not reached in either group. Overall response after progression was 61% and 59%, and 5-year estimated survival rate after progression was 69% and 74% in the R2 and R-chemo groups, respectively. The transformation rate per year in the R2 and R-chemo groups was 0.68% and 0.45%, and secondary primary malignancies occurred in 11% and 13% (P 5 .34), respectively. No new safety signals were observed. R2 continues to demonstrate comparable, durable efficacy and safety versus R-chemo in previously untreated patients with FL and provides an acceptable chemo-free alternative.

Author Affiliations

1University of Lille, CHU Lille, Lille, France; 2The University of Texas MD Anderson Cancer Center, Houston, TX; 3Nancy University Hospital, Vandoeuvre-lès-Nancy, France; 4Institut Paoli Calmettes, CRCM, AMU, Marseille, France; 5Centre Henri Becquerel, Rouen, France; 6Memorial Sloan Kettering Cancer Center, New York, NY; 7Hospices Civils de Lyon and Claude Bernard Lyon 1 Université, Lyon, France; 8CH de Dunkerque, Dunkerque, France; 9University of Washington, Seattle, WA; 10CHU Dijon-Bourgogne, Dijon, France; 11Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; 12Henri Mondor Université Hôpital, UPEC, Créteil, France; 13Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France; 14Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France; 15Washington University School of Medicine, St Louis, MO; 16Bordeaux University Hospital, Bordeaux, France; 17Hôpital Saint-Louis, Paris, France; 18Institut Gustave Roussy, Villejuif, France; 19Institut Curie, Paris, France; 20Annecy Hôpital, Annecy, France; 21CHU de Poitiers, Poitiers, France; 22Centre Hospitalier Métropole Savoie Chambéry, Chambéry, France; 23Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain; 24Hospital Clínic de Barcelona, Barcelona, Spain; 25CHU de Québec, Québec, Canada; 26Tokai University School of Medicine, Kanagawa, Japan; 27Instituto Português de Oncologia de Lisboa, Lisboa, Portugal; 28CHU UCL Namur, Yvoir, Belgium; 29ZNA Stuivenberg, Antwerp, Belgium; 30BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada; 31National Cancer Center Hospital, Tokyo, Japan; 32CHU Montpellier, Montpellier, France; 33Bristol Myers Squibb, Princeton, NJ

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????

Read More »

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Median progression-free survival (PFS) was significantly longer with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) than with R-GemOx (11.5 months vs 3.8 months). The overall response rate (ORR) was significantly higher with Mosun-Pola compared with R-GemOx (70% vs 40%; P < .0001), with complete response rates of 51% and 24%, respectively. Cytokine release syndrome (CRS) occurred in fewer than 5% of patients.

Read More »

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

The EPCORE NHL-2 phase 1b/2 trial evaluated fixed-duration epcoritamab plus R2 in R/R FL after at least one prior line, showing impressive efficacy with an overall response rate (ORR) of 96% and a complete response (CR) of 88%, and 2-year rates for remaining in CR (82%), progression-free survival (PFS) (76%), overall survival (OS) (90%), and freedom from next therapy (84%)—all with non-reached medians. High-risk groups did just as well, with CR rates of 90% in primary refractory, 82% in double refractory. MRD negativity was achieved by 86% overall. Safety was manageable, with mostly low-grade CRS (grade 1/2/3: 38%/11%/2%), neutropenia (65%), and COVID-19 (59%)—notably, no CRS-related discontinuations. This chemo-free, off-the-shelf regimen is delivering deep, durable remissions with practical outpatient dosing—something we’ve all been hoping to see for R/R FL.

Read More »

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma Available to Purchase

The phase 2 trial of Moga-CHOP (CHOP + mogamulizumab) in older patients with aggressive adult T-cell leukemia/lymphoma (ATL) demonstrated a significant improvement in 1-year PFS (36.2% vs 16% historical control), with a 1-year OS of 66.0% and a CR rate of 64.6%. The overall response rate (ORR) was high at 91.7%, and the median overall survival (OS) reached 1.6 years. Notably, CCR4 mutations and Moga-associated cutaneous AEs correlated with better OS, and the regimen was generally tolerable with no unexpected toxicities. Bottom line: Moga-CHOP is now a strong first-line option for older, transplant-ineligible ATL patients, and it’s encouraging to see these survival gains in a population with historically poor outcomes.

Read More »
Load More